SCHEMBL17317608

SCHEMBL17317608

COC(=O)C1CCN(CC(=O)N2CCc3c(C(F)(F)F)nn(Cc4ccc(F)cc4)c3C2)CC1

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ ENPP2 Q13822 1/20 0.44
▸ KCNK3 O14649 6/20 0.43
▸ DPP4 P27487 2/20 0.42
▸ DPP8 Q6V1X1 2/20 0.42
▸ DPP7 Q9UHL4 2/20 0.42
▸ DPP9 Q86TI2 1/20 0.42
▸ ALOX15 P16050 1/20 0.40
▸ TSHR P16473 2/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ GAA P10253 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ CCR1 P32246 1/20 0.39
▸ CACNA1G O43497 2/20 0.38
▸ TP53 P04637 1/20 0.37
▸ MAPT P10636 2/20 0.37
▸ POLB P06746 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17317792 0.95 KCNK3 (0.42) ENPP2KCNK3DPP4DPP8DPP7
SCHEMBL17317781 0.90 ENPP2 (0.52) ENPP2KCNK3DPP4DPP8DPP7
SCHEMBL17317605 0.90 SMN1; SMN2 (0.45) ENPP2KCNK3DPP4DPP8DPP7
SCHEMBL19110804 0.89 ENPP2 (0.42) ENPP2KCNK3SMN1; SMN2CACNA1GTP53
SCHEMBL17317696 0.89 KCNK3 (0.46) ENPP2KCNK3DPP4DPP8DPP7
SCHEMBL17317554 0.88 KCNK3 (0.45) KCNK3DPP4DPP8DPP7DPP9
SCHEMBL17317526 0.88 ENPP2 (0.50) ENPP2KCNK3DPP4DPP8DPP7
SCHEMBL17328186 0.87 KCNK3 (0.44) ENPP2KCNK3DPP4DPP8DPP7
SCHEMBL17317563 0.87 ENPP2 (0.47) ENPP2KCNK3DPP4DPP8DPP7
SCHEMBL17317829 0.85 KCNK3 (0.44) ENPP2KCNK3DPP4DPP8DPP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10144732-B2 ATX modulating agents BIOGEN MA INC. (US) 2018-12-04 — — US claimed
US-10144732-B2 ATX modulating agents BIOGEN MA INC. (US) 2018-12-04 — — US disclosed
US-20170197960-A1 ATX MODULATING AGENTS BIOGEN MA INC. 2017-07-13 — — US disclosed
US-20170197960-A1 ATX MODULATING AGENTS BIOGEN MA INC. 2017-07-13 — — US disclosed
EP-3152206-A1 ATX MODULATING AGENTS Biogen MA Inc. (US) 2017-04-12 — — EP disclosed
WO-2015188051-A1 ATX MODULATING AGENTS BIOGEN MA INC. (US) 2015-12-10 — — WO disclosed
WO-2015188051-A1 ATX MODULATING AGENTS BIOGEN MA INC. (US) 2015-12-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170197960-A1 ATX MODULATING AGENTS ENPP2, ATXN10, ATXN2 ENPP2 1/4885KCNK3 1825/4885DPP4 2232/4885
US-10144732-B2 ATX modulating agents ENPP2, ATXN10, ATXN2 ENPP2 1/4885KCNK3 1825/4885DPP4 2235/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback